Trans-genomic Inc, at the 2016 American Association for Cancer Research Annual Meeting, introduced the ICE COLD-PCR™ and the advantage of Multiplexed technology for liquid biopsy detection of tumor mutations. Mutations in certain actionable genes are analysed by the panel for breast cancer test for making the right treatment decisions, including PIK3CA exons 9 & 20, AKT1 (E17K) exon 4.
The results are available within 7-9 business days, for rest of the testing method, the entire time taken is approximately 4 weeks. This shortens the time to diagnosis and helps in taking decisions for the treatment, helping oncologists to select and initiate optimized treatment regimens for patients without delay. The Cancer can be detected at ease – Detect Cancer by a Simple Breath Test.
Targeting breast cancers with mutations (AKT1 or PIK3CA), there are many number of drug trials that are currently being conducted. The Breast Cancer Analysis Panel (an ultra-sensitive method) provides amplified sensitivity for DNA mutation detection in breast cancer patients down to 0.01 per cent for a 10 mL blood sample. It uniquely determines both known and unknown mutations and is designed to detect actionable mutations even prior to visible tumor growth.
Multiplexed ICE COLD-PCR achieves its ultra-high sensitivity through selective amplification of mutant DNA and also provides High Concordance in Clinical Testing. The result is precise to the point in sensitivity on identifying mutations with the most precise sequence alteration detection rates available. Cancer patient mutation detection and monitoring are supported by the clinical validity and utility of MX-ICP-based liquid biopsies.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
